X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (591) 591
Book Review (86) 86
Publication (39) 39
Newsletter (26) 26
Magazine Article (4) 4
Dissertation (3) 3
Book Chapter (2) 2
Newspaper Article (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rabeprazole (531) 531
index medicus (501) 501
humans (492) 492
male (374) 374
female (351) 351
middle aged (301) 301
omeprazole (272) 272
gastroenterology & hepatology (264) 264
adult (255) 255
proton pump inhibitors (241) 241
aged (194) 194
lansoprazole (180) 180
treatment outcome (173) 173
pharmacology & pharmacy (160) 160
helicobacter pylori (158) 158
helicobacter infections - drug therapy (155) 155
drug therapy, combination (139) 139
2-pyridinylmethylsulfinylbenzimidazoles (137) 137
proton pump inhibitor (125) 125
omeprazole - analogs & derivatives (113) 113
anti-ulcer agents - therapeutic use (110) 110
esomeprazole (109) 109
proton pump inhibitors - therapeutic use (106) 106
gastroesophageal reflux - drug therapy (105) 105
amoxicillin (99) 99
proton pump inhibitors - administration & dosage (99) 99
proton pump inhibitors - adverse effects (94) 94
prospective studies (88) 88
medicine & public health (87) 87
clarithromycin (83) 83
pantoprazole (83) 83
infection (82) 82
gastroesophageal reflux (81) 81
helicobacter pylori - drug effects (80) 80
young adult (80) 80
gastroesophageal-reflux disease (79) 79
anti-ulcer agents - administration & dosage (75) 75
anti-ulcer agents - adverse effects (74) 74
benzimidazoles - therapeutic use (71) 71
anti-bacterial agents - therapeutic use (69) 69
triple therapy (69) 69
eradication (67) 67
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (66) 66
amoxicillin - administration & dosage (65) 65
pharmacokinetics (65) 65
benzimidazoles - adverse effects (64) 64
efficacy (63) 63
double-blind method (62) 62
drug administration schedule (62) 62
drug interactions (62) 62
amoxicillin - therapeutic use (61) 61
anti-bacterial agents - administration & dosage (60) 60
rabeprazole - administration & dosage (60) 60
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (58) 58
gastroesophageal reflux disease (58) 58
management (57) 57
omeprazole - therapeutic use (57) 57
gastroenterology (56) 56
omeprazole - administration & dosage (56) 56
aged, 80 and over (55) 55
therapy (55) 55
cytochrome p-450 cyp2c19 (54) 54
time factors (54) 54
adolescent (53) 53
care and treatment (52) 52
cyp2c19 (52) 52
double-blind (52) 52
genotype (52) 52
helicobacter infections - microbiology (52) 52
omeprazole - adverse effects (51) 51
benzimidazoles - administration & dosage (50) 50
cross-over studies (50) 50
internal medicine (50) 50
2-pyridinylmethylsulfinylbenzimidazoles - adverse effects (49) 49
intragastric ph (48) 48
clarithromycin - administration & dosage (47) 47
metaanalysis (46) 46
pharmacology/toxicology (46) 46
aryl hydrocarbon hydroxylases - genetics (45) 45
metabolism (45) 45
oncology (45) 45
peptic ulcer - drug therapy (45) 45
clarithromycin - therapeutic use (44) 44
medical colleges (44) 44
analysis (43) 43
dosage and administration (43) 43
drug therapy (43) 43
anti-bacterial agents - adverse effects (42) 42
esophagitis (42) 42
helicobacter-pylori infection (42) 42
hepatology (42) 42
proton-pump inhibitors (42) 42
rabeprazole - therapeutic use (42) 42
dose-response relationship, drug (41) 41
health aspects (41) 41
japan (41) 41
metronidazole (41) 41
cytochrome p-450 (40) 40
hydrogen-ion concentration (39) 39
breath tests (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (598) 598
Japanese (8) 8
Korean (6) 6
French (4) 4
Russian (3) 3
Spanish (2) 2
Chinese (1) 1
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Gastroenterology, ISSN 0002-9270, 07/2016, Volume 111, Issue 7, pp. 949 - 956
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2013, Volume 71, Issue 6, pp. 1635 - 1643
The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its... 
Medicine & Public Health | Ketoconazole | Esomeprazole | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | CYP3A4 | Pazopanib | RABEPRAZOLE | HEALTHY-SUBJECTS | 24-H | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | INHIBITOR | PHASE-I | DRUG-INTERACTION | Neoplasms - metabolism | Proton Pump Inhibitors - pharmacology | Esomeprazole - administration & dosage | Cytochrome P-450 CYP3A | Ketoconazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Male | Ketoconazole - pharmacology | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Angiogenesis Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Pyrimidines - administration & dosage | Angiogenesis Inhibitors - pharmacokinetics | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Cytochrome P-450 CYP3A Inhibitors | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Ketoconazole - adverse effects | Sulfonamides - administration & dosage | Care and treatment | Metabolites | Analysis | Cytochrome P-450 | Tumors | Antiulcer drugs | Index Medicus
Journal Article
Stroke, ISSN 0039-2499, 03/2015, Volume 46, Issue 3, pp. 722 - 731
BACKGROUND AND PURPOSE—There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the... 
LANSOPRAZOLE | drug interactions | PROPENSITY SCORE | CARDIOVASCULAR EVENTS | CORONARY | OMEPRAZOLE | stroke | CLINICAL NEUROLOGY | pharmacoepidemiology | proton pump inhibitors | CONCOMITANT USE | platelet aggregation inhibitors | cohort studies | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | OUTCOMES | Medicaid | JAPANESE PATIENTS | ARTERY-DISEASE | Rabeprazole - adverse effects | Esomeprazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Male | Risk | Drug Therapy, Combination - adverse effects | Stroke - chemically induced | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Stroke - epidemiology | Retrospective Studies | Brain Ischemia - chemically induced | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Data Interpretation, Statistical | Stroke - prevention & control | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Proportional Hazards Models | Omeprazole - adverse effects | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Lansoprazole - adverse effects | Aged | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Rabeprazole - administration & dosage | Index Medicus | Pharmacoepidemiology | Stroke | Drug interactions | Cohort studies | Platelet aggregation inhibitors | Proton pump inhibitors
Journal Article
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2016, Volume 14, Issue 6, pp. 809 - 815.e1
Journal Article
Helicobacter, ISSN 1083-4389, 06/2013, Volume 18, Issue 3, pp. 180 - 186
Background The eradication rate with PPI-based standard triple therapy for Helicobacter pylori infection has fallen considerably. One recent innovation is... 
quadruple | concomitant | Helicobacter pylori | eradication | sequential | Quadruple | Sequential | Eradication | Concomitant | METAANALYSIS | MANAGEMENT | CONSENSUS CONFERENCE | CLARITHROMYCIN RESISTANCE | REGIMEN | MICROBIOLOGY | KOREA | TRIAL | QUADRUPLE THERAPY | TRIPLE THERAPY | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Proton Pump Inhibitors - pharmacology | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Rabeprazole | Anti-Bacterial Agents - therapeutic use | Proton Pump Inhibitors - administration & dosage | Metronidazole - therapeutic use | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Anti-Ulcer Agents - pharmacology | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Anti-Ulcer Agents - therapeutic use | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Breath Tests | Treatment Outcome | Proton Pump Inhibitors - therapeutic use | Pilot Projects | Urea - therapeutic use | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | Aged | Anti-Bacterial Agents - pharmacology | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Helicobacter Infections - microbiology | Urea | Care and treatment | Patient outcomes | Amoxicillin | Helicobacter infections | Index Medicus
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 01/2012, Volume 35, Issue 1, pp. 56 - 65
Background The eradication rates following standard triple therapy for Helicobacter pylori infection are declining worldwide. Recent studies have shown that... 
METAANALYSIS | MANAGEMENT | EFFICACY | ERADICATION RATES | PROTON-PUMP INHIBITOR | KOREAN PATIENTS | PHARMACOLOGY & PHARMACY | QUADRUPLE | GASTROENTEROLOGY & HEPATOLOGY | ANTIMICROBIAL RESISTANCE | FAILURE | CONSENSUS REPORT | Humans | Middle Aged | Male | Rabeprazole | Peptic Ulcer - microbiology | Time Factors | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Republic of Korea | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Endoscopy, Gastrointestinal | Treatment Outcome | Anti-Ulcer Agents - administration & dosage | Amoxicillin - adverse effects | Aged | Helicobacter pylori - isolation & purification | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Helicobacter Infections - microbiology | Medical colleges | Medical research | Clinical trials | Standards | Helicobacter pylori | Amoxicillin | Medicine, Experimental | Medical care | Helicobacter infections | Comparative analysis | Health aspects | Quality management | Infection | Clarithromycin | Hospitals | Metronidazole | Index Medicus
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 03/2012, Volume 27, Issue 3, pp. 504 - 509
Background and Aims:  The eradication rate of proton pump inhibitor (PPI)‐based triple therapy for Helicobacter pylori (H. pylori) infection has decreased,... 
Helicobacter pylori | ten‐day sequential therapy | proton pump inhibitor‐based triple therapy | Korea | Ten-day sequential therapy | Proton pump inhibitor-based triple therapy | METAANALYSIS | MANAGEMENT | STANDARD TRIPLE THERAPIES | CLARITHROMYCIN RESISTANCE | ADULTS | HELICOBACTER-PYLORI INFECTION | ERADICATION THERAPY | proton pump inhibitor-based triple therapy | ten-day sequential therapy | GASTROENTEROLOGY & HEPATOLOGY | DURATION | Humans | Middle Aged | Male | Rabeprazole | Drug Therapy, Combination - adverse effects | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Republic of Korea | Proton Pump Inhibitors - adverse effects | Anti-Infective Agents - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Breath Tests | Chi-Square Distribution | Drug Therapy, Combination - methods | Medication Adherence | Anti-Infective Agents - administration & dosage | Intention to Treat Analysis | Amoxicillin - adverse effects | Aged | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Drug resistance in microorganisms | Amoxicillin | Penicillin | Helicobacter infections | Antibacterial agents | Antiulcer drugs | Index Medicus
Journal Article
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2015, Volume 13, Issue 5, pp. 895 - 905.e5